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When renal function diminishes, secondary hyperparathyroidism  with  develop in response to worsening of kidney function 
and declined phosphate excretion (1). Dysregulation of 
phosphorous and calcium  homeostasis leads to decreased 
kidney phosphate excretion, raised serum phosphorous, 
reduced synthesis of calcitriol, and  elevated levels of 
the phosphatonin fibroblast growth factor 23 (FGF-23) 
(2-4). These alterations result in parathyroid hyperplasia 
and enhanced synthesis and secretion of parathyroid 
hormone participating to the development of a vicious 
cycle (3-5). Hence, continuous stimulus of the parathyroid 
glands by a mixture of decreased extracellular ionized 
calcium concentration, elevated extracellular phosphate 
concentration, and significantly reduced serum calcitriol 
leads to increased parathormone synthesis and release 
(3-7). Together, elevated FGF-23 expression down-
regulates residual kidney 25(OH)-1-hydroxylase, which 
aggravates the deficiency of calcitriol, working as an 
additional handler to hyperparathyroidism. Even at 
early phases in the development of hyperparathyroidism, 
these modifications are compounded by variable under-
expression of the calcium-sensing receptor and vitamin 
D receptor, giving the parathyroid cells incapable to 
react appropriately to ambient calcium and/or calcitriol. 
The ensuing increase in proliferative activity in the 
parathyroid glands finally leads to parathyroid hyperplasia 
(2-6). Current knowledge of the molecular mechanisms 
following phosphorous homeostasis has shown FGF-
23 and its receptor fibroblast growth factor receptor 1 
(FGFR1) have important role. FGF-23 is a hormone 
which its production in the osteocytes and osteoblasts 
is provoked by phosphate increment and calcitriol raise. 
FGF-23 binds to and activates FGFR1, which is functional 
merely if co-expressed with the Klotho transmembrane 
protein, as a Klotho-FGF receptor complex. It was 
found that, in the proximal tubule, FGF-23 diminishes 
phosphate reabsorption by moderating the expression of 
type II sodium phosphate co-transporters (3-7). Hence, 
rises in both serum FGF-23 and parathormone in patients 
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Secondary hyperparathyroidism is a progressive disease 
common in patients with chronic renal failure and with 
serious concerns for patient health. If unsuccessfully 
controlled, secondary hyperparathyroidism develops 
and can lead to soft tissue calcification, bone disease, 
and vascular calcification, which adversely impact 
mortality and morbidity. Conventional therapies 
that target vitamin D and phosphorous levels are 
not without disadvantages. The appearance of the 
calcimimetics and a better understanding of the 
strengths and limitations of native and active vitamin 
D compounds have advanced the treatment options for 
patients with secondary hyperparathyroidism. 
with chronic renal failure decrease the proximal tubular 
reabsorption of phosphate and keep normo-phosphatemia 
in most patients till the glomerular filtration rate decreases 
below 20 ml/min. Predictably, as chronic renal failure 
progresses, these negative feedback loops are progressively 
disrupted and finally unable to keep phosphate 
homeostasis (4-9). FGF-23 also reduces parathormone 
synthesis directly, while indirectly enhancing synthesis 
via reduction of kidney calcitriol fabrication. Correlations 
between high FGF-23 level in patients on dialysis, 
refractory secondary hyperparathyroidism, and increased 
mortality have been detected. On the other hand, high 
phosphate increases parathyroid hyperplasia. While, 
there was no confirmation to propose the presence of a 
phosphorous receptor on the parathyroid gland, various 
studies propose that vitamin D pathways play a secondary 
task in the development of parathyroid gland hyperplasia 
and that signaling across the calcium-sensing receptor is 
enough to prevent parathyroid hyperplasia. Patients in 
the early phases of chronic renal failure do not frequently 
present any changes in their serum phosphate and calcium 
levels (7-10). However, their parathormone levels may be 
only marginally higher than normal values. Various new 
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publications have described raised levels of FGF-23 in 
chronic renal failure patients, which may help to control 
serum levels of phosphate and calcium. The provocations 
for secretion of FGF-23 in early chronic renal failure are 
not completely found, and this is under investigation (6-
11). FGF-23 does not seem to be an acute postprandial 
regulator of phosphaturia in chronic renal failure, however 
inappropriate postprandial hypocalcemia could represent 
a previously unreported mechanism of secondary 
hyperparathyroidism in chronic renal failure. Studies on 
the effect of FGF-23 on parathyroid function in normal 
and hyperplastic parathyroid glands revealed that FGF-23 
diminished parathormone secretion and cell proliferation 
and increased calcium-sensing receptor and vitamin D 
receptor expression in normal glands (2-6,9-12). On the 
contrary, FGF-23 did not have an effect on hyperplastic 
glands. Thus, secondary hyperparathyroidism is a 
progressive disease common in patients with chronic renal 
failure and with serious concerns for patient health. If 
unsuccessfully controlled, secondary hyperparathyroidism 
develops and can lead to soft tissue calcification, bone 
disease, and vascular calcification, which adversely 
impact mortality and morbidity (10-15). Conventional 
therapies that target vitamin D and phosphorous levels 
are not without disadvantages. The appearance of the 
calcimimetics and a better understanding of the strengths 
and limitations of native and active vitamin D compounds 
have advanced the treatment options for patients with 
secondary hyperparathyroidism (12-15).
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